Alnylam Pharmaceuticals
ALNY
#1066
Rank
A$31.41 B
Marketcap
A$234.53
Share price
-5.17%
Change (1 day)
-65.78%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): A$8.16

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$7.86. In 2025 the company made an earnings per share (EPS) of A$2.93.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$8.16178.76%
2025A$2.93
2023A-$5.02-62%
2022A-$13.2029.03%
2021A-$10.23-3.36%
2020A-$10.59-8.48%
2019A-$11.577.67%
2018A-$10.7539.74%
2017A-$7.6912.94%
2016A-$6.8138.84%
2015A-$4.90-32.88%
2014A-$7.31259.44%
2013A-$2.03-31.25%
2012A-$2.96

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$9.47 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$2.70-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$59.57 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.74-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.04-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.13-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$0.90-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A-$4.73-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA